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In this issue of the British Journal ofCancer, reports from Japan
(Ando et al) and the Netherlands (Herben et al) add to the rapidly
growing number of publications concerning the DNA-topoiso-
merase I inhibitors, and their place in current and future oncolog-
ical practice. Combining inhibitors of both topoisomerase I and
topoisomerase II enzymes is one ofthosehighly promising clinical
scenarios that arises out of the rapidly expanding knowledge of
intracellular processes, and continues to drive modern oncological
research. However, clinical trials based on translational research
often raise more questions than answers, and the field oftopoiso-
merase inhibition is no exception.
DNA topoisomerase I and II are enzymes that bind to super-
coiled DNA, forming a cleavable complex, and through strand
breakage, passage and religation allow a wide variety of essential
DNA metabolic reactions, including replication and repair, to take
place (reviewed in Pommier, 1993). These enzymes are function-
ally related, work together and appear to be essential to maintain
cellular viability throughout the cell cycle. As it was shown in the
1980s that the cleavable complex could be stabilized by known
cytotoxic drugs such as doxorubicin, etoposide and camptothecin
(Tewey et al, 1984; 1985), resulting in interference with the strand
breakage-religation catalytic cycle and subsequent cell death,
much research has taken place into the development ofagents that
exploit this novel nuclear target. Established inhibitors oftopoiso-
merase II include the anthracycline antibiotics (e.g. doxorubicin)
and the epipodophyllotoxins (etoposide), which were not devel-
oped on the basis ofrational drug design against a specific cellular
target, and are not 'pure' topoisomerase II inhibitors (Baguely et
al, 1991). The only specific topoisomerase I inhibitors are the
camptothecins (Hsaing et al, 1988), and the lead compound,
camptothecin (Wall et al, 1966), was deemed too toxic for further
clinical development in early phase II studies, despite promising
preclinical activity (Gottlieb et al, 1972; Moertel et al, 1972).
However, the development of water-soluble synthetic/semi-
synthetic analogues of camptothecin such as irinotecan (CPT-11)
and topotecan, and the discovery that topoisomerase I levels were
higher in some tumours compared with normal tissues (Giovanella
et al, 1989; Van der Zee et al, 1991) has led to renewed interest in
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Both irinotecan and topotecan have broad anti-tumour activity,
which has been confirmed in phase 1/11 studies (reviewed in
Dancey and Eisenhauer, 1996). Irinotecan has shown impressive
results in the treatment ofNSCLC and colorectal cancers, although
diarrhoea remains a major clinical problem. Topotecan has a more
favourable toxicity profile, and its activity against ovarian cancer
and SCLC has prompted further development strategies in these
two tumour types. However, the optimal dosing schedule for this
agent remains uncertain. Despite this encouraging anti-tumour
activity, resistance to topoisomerase I inhibitors (and topoiso-
merase II inhibitors) occurs, resulting in failure to achieve long-
term remissions. This resistance is partly mediated through
overexpression of the p-glycoprotein transmembrane pump/MDR
phenotype (Moscow et al, 1988), but other mechanistic considera-
tions also apply. The cytotoxicity of topoisomerase I inhibitors is
dependent upon levels of topoisomerase I in the tumour, and on
DNA replication (Zhang et al, 1990; Del Bino et al, 1991). In addi-
tion, cells resistant to topoisomerase I inhibitors have been shown
to contain either low levels of topoisomerase I or structurally
altered forms of the enzyme (Pommier, 1993). Moreover, cellular
expression of one of the topoisomerase II isoenzymes, topoiso-
merase Ila, varies throughout the cell cycle, being non-detectable
in Go, but rapidly rising throughout S phase to peak at G2/M
(Woessner et al, 1991). The implication here, is that tumours with
only a small fraction of cells undergoing proliferation at one time
will be less likely to respond to topoisomerase II poisons acting
primarily through topoisomerase Ila. It has been shown in many
preclinical studies that cross-resistance to topoisomerase III
inhibitors is unusual in resistant cell lines (Ferguson et al 1988;
Tsuruo et al 1988; Matsuo et al 1990), and also that frequent alter-
ations in the regulation of one topoisomerase are compensated by
alterations in the other (Lefevre et al, 1991). Topoisomerase I-defi-
cient cells demonstrate up-regulated expression of topoisomerase
II (Gupta et al, 1988; Eng et al, 1990), and intriguingly, cell lines
with deficient topoisomerase I levels/activity appear to be more
sensitive to treatment with topoisomerase II inhibitors (Sugimoto
et al, 1990). The reverse situation, that the development of
resistance to topoisomerase II inhibitors confers increased sensi-
tivity to subsequent treatment with topoisomerase I inhibitors has
also been reported (Beck et al, 1989; Tan et al, 1989; Sugimoto et
al, 1990). This 'collateral sensitivity', resulting from a compen-
satory role of one topoisomerase enzyme for the other, led to the
hypothesis that a combination oftopoisomerase I and II inhibitors
could demonstrate at least additive and possibly synergistic cyto-
toxicity.
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Attractive though this concept is, preclinical work has demon-
strated conflicting results when topoisomerase I and II inhibitors
are combined. Indeed, antagonistic effects on cytotoxicity were
observed when topoisomerase I/11 inhibitors were administered
concurrently to either hamster lung fibroblasts (D'Arpa et al,
1990) or human leukaemia cells (Kaufmann et al, 1991), whereas
the anticipated additive/synergistic effects were observed with
human lung cancer cells, nude mice xenografts (Takada et al,
1992) or acute lymphoblastic leukaemia cells (Kano et al, 1992).
However, when topoisomerase I/II inhibitors were administered
sequentially, additive/synergistic cytotoxicity was observed
almost universally. Kim et al (1992) showed that pretreating
human tumour xenografts with irinotecan both increased tumour
topoisomerase II mRNA levels and demonstrated enhanced sensi-
tivity to doxorubicin treatment. In addition, sequential treatment of
human colorectal cancer cell lines with camptothecin followed by
etoposide resulted in additive cytotoxicity, and interestingly, that
the order of administration of topoisomerase I or II inhibitor did
not seem to be important (Bertrand et al, 1992). Overall, these
results seemed to suggest that concurrent administration of topoi-
somerase I/II inhibitors was unlikely to be beneficial, but that clin-
ical studies would be required to formally examine whether or not
sequential administration of these agents offered any advantage
over monotherapy.
Unfortunately, subsequent clinical trials have by and large failed
to confirm the potential therapeutic advantage alluded to in the
preclinical data. Phase I and II trials combining topoisomerase I
and II inhibitors either sequentially or simultaneously generally
demonstrate neutropenia as the major dose-limiting toxicity,
whether or not growth factor support is used. Neutropenia (and
particularly diarrhoea with irinotecan) does appear to be more
severe when sequential administration is performed (Eckard et al,
1993; Schneider et al, 1994), suggesting at least additive myeloge-
nous toxicity. In this month's BJC (p. 000), Ando et al report their
results using a sequential regimen ofirinotecan and etoposide plus
G-CSF in 27 untreated NSCLC patients. In this study, patients
received either irinotecan before etoposide or etoposide before
irinotecan, to determine whether or not the order oftopoisomerase
MI/I inhibitor administration had any impact on subsequenttoxicity.
As in this group's previous phase I study, in which they used a
simultaneous regimen of irinotecan and etoposide (Karato et al,
1993), the dose-limiting toxicities were diarrhoea and severe
neutropenia, despite concurrent growth factor support. There was
no difference observed (although patient numbers were small) in
toxicities among patients receiving either irinotecan or etoposide
first in the combination, and although the AUC of irinotecan was
significantly higher when this drug followedetoposide administra-
tion, this was not associated with increased haemalogical toxicity.
Only 12 patients managed to receive two cycles (only one received
three cycles) with a 37% dropout rate owing to toxicity or patient
refusal. Responses were low (threepartial responses, all in patients
who received 2 or three cycles), probably owing to the inability to
deliver enough courses of treatment. Also in this issue (p. 000)
Herben et al report on a phase I trial using sequential administra-
tion of topotecan followed by oral etoposide in patients with
refractory tumours. As with earlier studies (Eckard et al 1993),
neutropenia was found to be more severe than expected from
either agent administered alone, and neither agent was able to be
administered at its individual MTD. Anti-tumour efficacy was
confined to a single partial response in a patient with pretreated
metastatic ovarian cancer, although 64% of the patients remained
stable without disease progression for at least 4 months.
So what can we conclude from these data, and where does this
leave the combination of topoisomerase II inhibitors in clinical
practice? The overall impression from the reported studies using
concurrent administration of topoisomerase I/11 inhibitors, both
preclinical and clinical, is that anti-tumour efficacy is not signifi-
cantly improved, although treatment-related toxicities of the
combination given this way appear acceptable. Indeed, Oshita and
colleagues (1997) have recently reported the results oftheir phase
II trial using concurrent irinotecan and etoposide in untreated
NSCLC patients, which produced a lower response rate for the
combination than would have been expected for irinotecan alone,
based upon current single-agent activity data. Moreover, the hope
from the preclinical data that sequential administration oftopoiso-
merase I/II inhibitors will result in at least additive and possibly
synergistic cytotoxicity, seems to have translated into the clinical
setting as severe myelogenous toxicity, with little evidence, as yet,
for improved efficacy over the individual agents when used as
monotherapy. In the case ofirinotecan, diarrhoea remains a signif-
icant problem when this agent is administered alone, and novel
solutions to this toxicity are needed before it will find widespread
acceptance in the oncological community. A possible reason for
the lack of enhanced efficacy is that the degree of normal tissue
toxicity prevents the delivery of sufficient doses to effect a
response in studies in which the tumours are relatively chemo-
resistant. One could conclude that the topoisomerase inhibitors in
current practice are too non-selective, and therefore produce
damage to normal cells via other mechanisms, for example free
radical generation, covalent DNA binding etc, which narrows the
therapeutic index to a critical degree for clinical acceptability.
Clearly, the use of haemopoietic growth factors is unable to
completely abrogate the dose-limiting myeloid toxicities of the
combinations, and therefore the use of peripheral blood stem cell
transplantation (PBSCT) is a possible solution. However, as long
as non-myeloid toxicities are prevalent, such as diarrhoea, these
techniques are unlikely to be successful. In addition, clinical
evidence of higher anti-tumour efficacy for the combination over
single-agent therapy would be desirable before any dose-intensifi-
cation strategy with PBSCT support is envisaged. As there is no
clinical evidence of this to date, the use of PBSCT in delivering
standard dose combinations of topoisomerase 111 inhibitors must
be considered an expensive and highly speculative way of deliv-
ering such regimens. Combinations oftopoisomerase II inhibitors
with topotecan may be more fruitful than with irinotecan, as this
agent has a better toxicity profile. However, there is little
convincing clinical evidence forcollateral sensitivity with topoiso-
merase I/IIinhibitors. Perez-Soleret al (1996) recently reported 32
patients with SCLC refractory to etoposide (and therefore possibly
with up-regulated topoisomerase I levels) treated subsequently
with topotecan. The low response rate observed (11%) suggests
that such etoposide-resistant tumours do not select for cells that
depend more on topoisomerase I than topoisomerase II for DNA
synthesis. At this stage therefore, sequential use oftopoisomerase
I/II inhibitors appears to have more impact on normal tissue toxi-
city than anti-tumour efficacy, and this will need to be addressed
in further preclinical studies. In addition, future clinical trials
involving topoisomerase I/II inhibitors should attempt to examine
levels of these enzymes in clinical material obtained after treat-
ment with the inhibitor.
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Finally, combinations of topoisomerase I inhibitors with alkyl-
ating agents orplatinumcompounds mayhave more to offer, as one
could hypothesize that camptothecins may inhibit topoisomerase
I-mediated repair of drug-induced DNA damage. In vitro and in
vivo work has demonstrated synergistic cytotoxicity ofthe sequen-
tial administration of camptothecin with both cisplatin and
cyclophosphamide (Kano et al, 1992), and has also showed that
irinotecan plus cisplatin was superior to combinations of cisplatin
and vindesine or etoposide against human lung cancer cell lines
(Kuraishi et al, 1992). Furthermore, phase I/II clinical trials ofthis
combination inuntreated NSCLC and SCLC (extensive and limited
stage) patients has demonstrated impressive partial response rates
of54% (Masudaetal, 1994) and78% (Fujiwaraetal, 1994) respec-
tively. Toxicities appear to be acceptable, and such encouraging
results merit further assessment in the form ofrandomized compar-
isons with established chemotherapeutic regimens.
Although the combination of topoisomerase I and II inhibitors
does not appear to be feasible in the clinic, this should not prevent
further preclinical evaluation of such novel agents and schedules.
As pointed out by Dancy and Eisenhauer (1996) in a previous
editorial, 'preclinical-clinical dialogue must continue to further our
understanding of the determinants of toxicity, resistance and effi-
cacy. Such data will allow optimization of the use of these agents
and permit the development ofbetter analogues in this class'.
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